OCUL
Price
$11.87
Change
-$0.43 (-3.50%)
Updated
Aug 25, 04:59 PM (EDT)
Capitalization
2.07B
77 days until earnings call
PVLA
Price
$50.10
Change
-$3.32 (-6.21%)
Updated
Aug 25, 04:59 PM (EDT)
Capitalization
554.42M
Interact to see
Advertisement

OCUL vs PVLA

Header iconOCUL vs PVLA Comparison
Open Charts OCUL vs PVLABanner chart's image
Ocular Therapeutix
Price$11.87
Change-$0.43 (-3.50%)
Volume$27.45K
Capitalization2.07B
Palvella Therapeutics
Price$50.10
Change-$3.32 (-6.21%)
Volume$2.1K
Capitalization554.42M
OCUL vs PVLA Comparison Chart in %
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PVLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. PVLA commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and PVLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (OCUL: $12.30 vs. PVLA: $53.42)
Brand notoriety: OCUL and PVLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 63% vs. PVLA: 99%
Market capitalization -- OCUL: $2.07B vs. PVLA: $554.42M
OCUL [@Biotechnology] is valued at $2.07B. PVLA’s [@Biotechnology] market capitalization is $554.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.72B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whilePVLA’s FA Score has 1 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • PVLA’s FA Score: 1 green, 4 red.
According to our system of comparison, PVLA is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 3 TA indicator(s) are bullish while PVLA’s TA Score has 3 bullish TA indicator(s).

  • OCUL’s TA Score: 3 bullish, 4 bearish.
  • PVLA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both OCUL and PVLA are a bad buy in the short-term.

Price Growth

OCUL (@Biotechnology) experienced а -2.54% price change this week, while PVLA (@Biotechnology) price change was +12.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was +18.77%, and the average quarterly price growth was +29.32%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.07B) has a higher market cap than PVLA($554M). PVLA YTD gains are higher at: 345.167 vs. OCUL (44.028). PVLA has higher annual earnings (EBITDA): -23.27M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. PVLA (70.4M). OCUL has higher revenues than PVLA: OCUL (56.7M) vs PVLA (0).
OCULPVLAOCUL / PVLA
Capitalization2.07B554M373%
EBITDA-200.5M-23.27M862%
Gain YTD44.028345.16713%
P/E RatioN/A14.22-
Revenue56.7M0-
Total Cash391M70.4M555%
Total Debt76.9MN/A-
FUNDAMENTALS RATINGS
OCUL vs PVLA: Fundamental Ratings
OCUL
PVLA
OUTLOOK RATING
1..100
6038
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3835
P/E GROWTH RATING
1..100
10012
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (54) in the Pharmaceuticals Other industry is in the same range as PVLA (70) in the null industry. This means that OCUL’s stock grew similarly to PVLA’s over the last 12 months.

OCUL's Profit vs Risk Rating (83) in the Pharmaceuticals Other industry is in the same range as PVLA (100) in the null industry. This means that OCUL’s stock grew similarly to PVLA’s over the last 12 months.

PVLA's SMR Rating (97) in the null industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that PVLA’s stock grew similarly to OCUL’s over the last 12 months.

PVLA's Price Growth Rating (35) in the null industry is in the same range as OCUL (38) in the Pharmaceuticals Other industry. This means that PVLA’s stock grew similarly to OCUL’s over the last 12 months.

PVLA's P/E Growth Rating (12) in the null industry is significantly better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that PVLA’s stock grew significantly faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULPVLA
RSI
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 25 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PVLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KCSSX13.780.43
+3.22%
Knights of Columbus Small Cap S
FZAMX24.720.61
+2.53%
Fidelity Advisor Mid Cap II Z
FSWCX13.300.25
+1.92%
Fidelity SAI US Value Index
BDAUX32.040.49
+1.55%
Baron Durable Advantage R6
LHCTX19.640.17
+0.87%
Lord Abbett Health Care R5

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+1.40%
EYPT - OCUL
65%
Loosely correlated
+1.98%
CRNX - OCUL
55%
Loosely correlated
+5.17%
IDYA - OCUL
55%
Loosely correlated
+1.99%
DNLI - OCUL
55%
Loosely correlated
+1.71%
RVMD - OCUL
55%
Loosely correlated
+1.45%
More

PVLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PVLA has been loosely correlated with DRMA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PVLA jumps, then DRMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PVLA
1D Price
Change %
PVLA100%
+4.11%
DRMA - PVLA
42%
Loosely correlated
+2.81%
OCUL - PVLA
34%
Loosely correlated
+1.40%
RGNX - PVLA
33%
Poorly correlated
+11.10%
FOLD - PVLA
32%
Poorly correlated
+0.13%
ERAS - PVLA
32%
Poorly correlated
+6.67%
More